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Abstract. Tumor heterogeneity and the poor outcome of 
breast cancer (BC) patients have led researchers to define new 
markers of this disease. In recent years, microRNA expression 
patterns have proven to be valuable disease indicators. The 
level of miR-203a, in particular, was shown to be altered in 
different types of cancer. The objective of the present study 
was to assess the relationship between miR-203a expres-
sion and clinicopathological features of BC in a Portuguese 
cohort. The expression levels of miR-203a were analyzed in 
109 formalin-fixed paraffin-embedded paired normal and 
tumor tissue samples. Significant overexpression of miR-203a 
in the tumor tissues was found (1.7-fold higher) compared to 
the  expression in the normal adjacent tissues (p=0.003). In 
addition, several clinicopathological characteristics presented 
an association with higher miR-203a expression levels. 
Tumors with diameter ≤18.5 mm (1.5-fold; p=0.019), tumors 
positive for estrogen receptor (fold-change, 1.71; p=0.042), 
progesterone receptor (fold-change, 1.50; p=0.046) and nega-
tive for HER2 (fold-change, 1.50; p=0.016) and high Ki-67 
index (fold-change, 2.60; p=0.024) presented a significant 
difference in miR-203a expression compared with adjacent 
normal tissues. Tumors without invasion of lymph nodes also 
presented higher expression of miR-203a (fold-change, 2.40; 
p=0.004). With regard to histological classification, ductal 
carcinomas in situ (fold-change, 2.20; p=0.028) and invasive 
carcinoma NOS (fold-change, 1.71; p=0.009) displayed signifi-
cantly higher expression of miR-203a. Moreover, we found a 
significant downregulation of miR-203a with increased stage 
in invasive lobular carcinomas, suggesting that miR-203a 
could represent a potential marker to discriminate stages in 
invasive lobular carcinomas.
Introduction
Breast cancer (BC) remains a worldwide burden with an 
estimated incidence of more than 1.5 million new cases and 
approximately half a million deaths per year (1). Due to early 
detection, improvement in treatment options and changes in 
lifestyle paradigms, the mortality rates have been decreasing 
in developed countries. Conversely, developing countries are 
witnessing an increase in BC incidence and mortality rates, 
most probably due to the lack of awareness campaigns and 
changes in daily habits such as sedentary lifestyle, high 
consumption of sugars and fat that lead to overweight and 
obesity, known risk factors of BC (1). Moreover the propor-
tion of cases diagnosed in less developed countries is meagre 
when compared to developed regions thus leading to higher 
mortality rates (2).
Although the molecular mechanisms that underlie the 
development of breast cancer have been well investigated, our 
current knowledge is far from complete. BC is a heterogeneous 
malignancy. Clinical diagnosis and prescribed therapy relie 
on the TNM staging system based on tumor (T), node status 
(N) and metastasis (M). Estrogen and progesterone receptor 
status, human epidermal growth factor receptor 2 (HER2/
neu) status and the Ki-67 proliferative index, in addition 
to tumor-infiltrating lymphocytes, as well as the age of the 
patient, are used to classify BC into various subtypes (2-4). 
Nonetheless, these conventional breast cancer prognostic 
factors have intrinsic limitations, and their use does not allow 
an accurate prediction of treatment resistance or relapse. 
Defining new molecular prognostic factors to refine BC 
classification could be useful in improving the therapeutic 
schemes.
Recently, various microRNAs (miRNAs) have been char-
acterized and identified as regulators and/or biomarkers in 
breast cancer development, including initiation, metastasis and 
therapeutic resistance (5-11). miRNAs are small 18-22 nucleo-
tide RNA molecules that regulate protein expression by mostly 
binding to the 3'-UTR (3'-untranslated region) of mRNAs, 
thus inhibiting translation through repression or degradation 
of mRNAs (12,13). Due to their size, miRNAs are stable in 
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human samples and can easily be used as molecular signatures 
in cancer (14-20).
miR-203 was originally described as a keratinocyte-specific 
miRNA (21) but was soon shown to play an important role 
in bladder cancer (22) and to be epigenetically silenced in 
hematopoietic cancers (23). Several studies have shown an 
association between miR-203 and chemotherapeutic resistance 
to cisplatin (24), invasiveness (25,26), proliferation (26-29) and 
metastases (30,31), and as a biomarker (32,33). Some miR-203 
targets have been identified, such as BMI1, SNAI2, SOCS3, 
BIRC5 and LASP1 (24-26,28,34), but a complete picture of the 
expression of miR-203 in different cohorts of BC, its mecha-
nisms of action and the circuitry of its effects remain to be 
fully clarified.
With the aim of contributing to a better understanding of 
the role of miR-203a in breast cancer, this study reports on the 
assessment of miR-203a expression and clinicopathological 
features in a Portuguese population with breast carcinoma.
Materials and methods
Sample collection and processing. Patients with breast carci-
noma were recruited for the study at the Hospital de São José, 
from Centro Hospitalar de Lisboa Central, during 2013 and 
2014. Each patient signed a written informed consent form and 
this study was reviewed and approved by the Ethics Committees 
of the NOvA Medical School and of the Centro Hospitalar 
de Lisboa Central. All clinical information was gathered by 
trained and specialized clinicians. All samples originated 
from surgical sections (mastectomy or tumorectomy). A total 
of 109 formalin-fixed paraffin-embedded (ffPE) paired 
normal and tumor tissue samples were collected. Normal 
tissue was adjacent to the tumor and in all cases was confirmed 
by the pathology team as being only normal mammary tissue. 
Diagnosis and common immunohistochemical markers for 
breast cancer classification such as estrogen and progesterone 
receptor (ER and PR), HER2 amplification status and Ki-67 
proliferative index were evaluated by two highly trained and 
independent pathologists. Staging was performed by tumor (T), 
node (N) and metastasis (M) classification (35). The procedure 
for immunohistochemical detection was carried out according 
to the recommendations of the American Society of Clinical 
Oncology/College of American Pathologists (ASCO/CAP) 
guidelines (36,37) and the International Ki-67 in Breast 
Cancer Working Group (38) at the time of sample collection. 
With the existing canons at the time, the molecular classifica-
tion of breast tumors was as follows: luminal A: ER-positive 
or PR-positive and Ki-67 <13%; luminal B: ER-positive or 
PR-positive and Ki-67 ≥13%; HER2-positive: ER-negative 
and PR-negative, HER2-positive; triple-negative: ER-negative, 
PR-negative and HER2-negative.
Total RNA was purified from FFPE tissues using 
RecoverAll™ Total Nucleic Acid isolation kit (Ambion®) and 
according to the manufacturer's protocol with slight altera-
tions. Briefly, the samples were deparaffinized with xylol and 
digested with protease/digestion buffer. Microtube pestles were 
used to macerate hard samples during digestion. Then, nucleic 
acid was precipitated with a mixture of absolute ethanol/isola-
tion additive and the supernatant used in the filter cartridges 
to proceed with DNA digestion using a DNase/DNase buffer 
mixture. Total RNA containing miRNAs was eluted and 
preserved at -80˚C for further use.
miR-203a quantification by quantitative RT-PCR (RT-qPCR). 
Total RNA concentration was quantified using a NanoDrop™ 
spectrophotometer. miR-203a expression levels were quanti-
fied by RT-qPCR using cDNA Synthesis and SYBR®-Green 
Master Mix kits (Exiqon, Denmark) on an ABI 7300 real-time 
PCR machine, according to the manufacturer's instructions. 
For each cDNA synthesis experience a no-enzyme control was 
used to ensure that there was no contamination during cDNA 
synthesis, and for each sample a no-template control was used 
to detect any potential amplification of genomic DNA. U6 
snRNA was used as internal control for data normalization. 
Relative expression of miR-203a in each FFPE sample was 
determined by 2-ΔCt, where ΔCt is Ct (miR-203a) - median 
Ct (U6 snRNA). Fold-change was determined by 2-ΔΔCt, 
where ΔΔCt is ΔCt (tumor) - ΔCt (normal). All samples were 
analyzed in duplicate.
Statistical analysis. All statistical analyses were performed 
using the SPSS statistical software package version 21.0 (SPSS 
Inc., Chicago, IL, USA). Non-parametric Wilcoxon signed-rank 
test was used to analyze the differences between matched 
samples (normal vs. tumor tissues). The Mann-Whitney U test 
and Kruskal-Wallis test were used to analyze the differences 
of miR-203a expression levels in the tumor tissue according to 
the clinicopathological characteristics. for nominal variables, 
the relationships between clinicopathological characteristics 
and miR-203a status were studied using the Chi-square test 
and fisher's exact test.
Results
Study population description. Breast tumor and adjacent 
normal mammary tissues were collected from 109 patients. 
The study population comprised only Caucasian woman 
from the greater area of Lisbon and on the day of diagnosis 
the median age was 62 years (range, 30-85). The median age 
of menarche and menopause was 13 years (range, 8-17) and 
50 years (range, 36-59), respectively, and ~66% of the popula-
tion was diagnosed with breast carcinoma in post menopause 
status. Seventy-seven percent of the women had one or more 
pregnancies and ~73% had one or more children. Forty-five 
percent claimed to have taken birth control pills. Approximately 
50% were overweight or obese. Regarding general tumor 
characteristics, the median tumor size was 18.5 mm (range, 
6-130), ~51% showed no invasion of the lymph nodes, ~80% 
were ER-positive, 72.5% were PR-positive, and 13.8% showed 
high amplification of HER2 and 48% showed negative Ki-67 
proliferation index. The most common histological type was 
invasive carcinoma NOS (83.5% of the cases), followed by 
invasive lobular carcinoma (9.2%), ductal carcinoma in situ 
(6.4%) and invasive lobular and ductal carcinoma (0.9%). 
The most common molecular subtype was luminal A (47.4% 
of all cases). Luminal B represented ~40% of the remaining 
cases. Triple-negative subtype represented ~12% of the cases. 
The most frequent stage was II (46.8%) followed by I (37.6%) 
and III (8.3%). All these data, together with the stratification of 
several variables, is displayed in Tables I-III.
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Table I. Association of miR-203a relative expression with clinical characteristics of the breast cancer cases.
 Median relative expression
 of miR-203
 -------------------------------------------------------------
 n (%) Normal tissue Tumor tissue Tumor tissue/normal tissue P-valuea
No. of cases 109 (100) 0.07 0.12 1.7 0.002b
Age at diagnosis (years), n (%)
  30-39 3 (2.8) 0.04 0.07 1.75 0.593
  40-49 17 (15.6) 0.14 0.13 0.93 0.906
  50-59 27 (24.8) 0.14 0.15 1.07 0.657
  >60 54 (49.5) 0.04 0.11 2.75 0.001
  Missing 8 (7.3)
Age at menarche (years), n (%)
  ≤13 65 (59.6) 0.06 0.12 2.00 0.066
  >13 35 (32.1) 0.06 0.14 2.33 0.003
  Missing 9 (8.3)
Age at menopause (years), n (%)
  ≤50 44 (52.4) 0.04 0.14 3.50 <0.001
  >50 29 (34.5) 0.05 0.10 2.00 0.539
  Missing 11 (13.1)
Menopausal status, n (%)
  Pre 25 (22.9) 0.14 0.12 0.86 0.607
  Post 72 (66.1) 0.05 0.11 2.20 0.003
  Peri 1 (0.9)
  Missing 11 (10.1)
No. of pregnancies, n (%)
  0 15 (13.8) 0.07 0.15 2.14 0.972
  1-2 42 (38.5) 0.06 0.11 1.83 0.046
  3-4 27 (24.8) 0.08 0.11 1.38 0.416
  >4 15 (13.8) 0.04 0.16 4.00 0.001
  Missing 10 (9.2)
No. of children, n (%)
  0 21 (19.3) 0.04 0.12 3.00 0.295
  1-2 64 (58.7) 0.08 0.11 1.38 0.012
  3-4 12 (11.0) 0.08 0.12 1.50 0.657
  >4 4 (3.7) 0.03 0.21 7.00 0.068
  Missing 8 (7.3)
Age at first birth (years), n (%)
  <20 13 (11.9) 0.05 0.17 3.40 0.033
  20-30 45 (41.3) 0.09 0.12 1.33 0.074
  >30 12 (11.0) 0.04 0.09 2.25 0.182
  Missing 39 (35.8)
Breastfeeding, n (%)
  No 32 (29.4) 0.04 0.11 2.75 0.170
  Yes 67 (61.5) 0.08 0.13 1.62 0.002
  Missing 10 (9.2)
Oral contraceptive, n (%)
  No 48 (44.0) 0.04 0.11 2.75 0.130
  Yes 49 (45.0) 0.08 0.12 1.50 0.004
  Missing 12 (11.0)
ap<0.05 was considered significant according to the non-parametric Wilcoxon signed-rank test, unless otherwise specified; bp<0.05 was consid-
ered significant according to the non-parametric Mann-Whitney test. Significant results are indicated in bold.
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miR-203a is overexpressed in tumor tissues compared to normal 
tissues. There was a significant overexpression of miR-203a 
in the tumor tissues (1.7-fold higher) compared to the normal 
adjacent tissues from the 109 patients (p=0.003; Wilcoxon 
signed-rank test to matched samples) (Table I and fig. 1).
Association between miR-203a expression and reproductive 
characteristics. The evaluation of clinical variables (Table I) 
revealed a significantly different distribution in the 
fold-change of expression of miR-203a when considering 
the number of pregnancies (Kruskal-Wallis p=0.006; Fig. 2). 
Specifically, there was a higher fold-change of expression in 
woman with four or more pregnancies compared to the other 
classes (no pregnancies vs. >4, p=0.01; 1-2 vs. >4, p=0.03; 3-4 
vs. >4, p=0.01; Fig. 2). Significant differences in age were also 
found (fig. 3).
Using Wilcoxon signed-rank test to matched samples 
with the same variables, patients >60 years of age on the 
day of diagnosis (fold-change, 2.75; p=0.001), with menarche 
Table II. Association of miR-203a relative expression with the lifestyle habits of the breast cancer cases.
 Median relative expression of miR-203
 ---------------------------------------------------------------------------
 n (%) Normal tissue Tumor tissue Tumor tissue/normal tissue P-valuea
Body mass index, n (%)
  Underweight 2 (1.8) 0.22 0.31 1.41 0.655
  Normal 42 (38.5) 0.08 0.13 1.63 0.252
  Overweight 30 (27.5) 0.04 0.11 2.75 0.006
  Obese 23 (21.1) 0.06 0.11 1.83 0.073
  Missing 12 (11.1)
Smoking habit, n (%)
  No 73 (67.0) 0.05 0.13 2.60 0.001
  Yes 22 (20.2) 0.09 0.11 1.22 0.465
  Missing 14 (12.8)
Alcohol habits, n (%)
  No 54 (49.5) 0.07 0.13 1.86 0.059
  Sporadically 24 (22.0) 0.04 0.12 3.00 0.037
  Daily 17 (15.6) 0.14 0.12 0.86 0.607
  Missing 14 (12.8)
ap<0.05 was considered significant according to non-parametric Wilcoxon signed-rank test. Significant results are indicated in bold.
figure 1. Differences in miR-203a relative expression in tumor and adjacent 
normal tissues. The values of miR-203a expression levels are shown in arbi-
trary units as determined by 2-ΔCt method [ΔCt = Ct (miR-203a) - median Ct 
(U6 snRNA)]. Lines represent median with interquartile range. p<0.05 was 
considered significant according to the non-parametric Mann-Whitney test.
Figure 2. Differences in the fold-change in miR-203a expression between the 
numbers of pregnancies. The values of miR-203a expression levels are shown 
in arbitrary units as determined by 2-ΔΔCt method [ΔΔCt = ΔΔCt (tumor) - ΔCt 
(adjacent normal)]. Bars represents mean and error bars, SEM. p<0.05 was 
considered significant according to the non-parametric Kruskal-Wallis test.
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age >13 years (fold-change, 2.33; p=0.003) and menopause 
<50 years (fold-change, 3.50; p<0.001), showed a significant 
overexpression of miR-203a when comparing tumor 
tissues with normal adjacent tissues. Patients diagnosed in 
Table III. Association of miR-203a relative expression with the pathological characteristics of the breast cancer patients.
 Median relative expression
 of miR-203
 ------------------------------------------------------------
 n (%) Normal tissue Tumor tissue Tumor tissue/normal tissue P-valuea
Size of the tumor (mm), n (%)
  ≤18.5 54 (49.5) 0.08 0.12 1.50 0.019
  >18.5 54 (49.5) 0.06 0.12 2.00 0.076
  Missing 1 (1.0)
Lymph node invasion, n (%)
  No 52 (51.4) 0.05 0.12 2.40 0.013
  Yes 53 (47.7) 0.09 0.11 1.22 0.137
  Missing 4 (0.9) 
Estrogen receptor status, n (%)
  Negative 16 (14.7) 0.07 0.15 2.14 0.074
  Positive 87 (79.8) 0.07 0.12 1.71 0.042
  Missing 6 (5.5)
Progesterone receptor status, n (%)
  Negative 22 (20.2) 0.04 0.12 3.00 0.091
  Positive 79 (72.5) 0.08 0.12 1.50 0.046
  Missing 8 (7.3)
HER2 status, n (%)
  Negative 87 (79.8) 0.08 0.12 1.50 0.016
  Positive 15 (13.8) 0.72 0.73 1.01 0.609
  Missing 7 (6.4)
Ki-67 index status, n (%)
  Negative 53 (48.6) 0.05 0.13 2.60 0.024
  Positive 48 (44.0) 0.08 0.10 1.25 0.253
  Missing 8 (7.3)
Histological type, n (%)
  Ductal carcinoma in situ 7 (6.4) 0.05 0.11 2.20 0.028
  Invasive carcinoma NOS 91 (83.5) 0.07 0.12 1.71 0.009
  Invasive lobular carcinoma 10 (9.2) 0.13 0.11 0.84 0.575
  Invasive lobular and ductal carcinoma 1 (0.9)
Molecular type, n (%)
  Luminal A 48 (47.5) 0.07 0.13 1.86 0.054
  Luminal B (HER2-) 27 (26.7) 0.08 0.11 1.38 0.527
  Luminal B (HER2+) 13 (12.9) 0.07 0.08 1.14 0.221
  Triple-negative 12 (11.9) 0.06 0.15 2.50 0.139
  HER2+ 1 (1.0)
Stage, n (%)
  0 7 (6.4) 0.05 0.11 2.20 0.028
  I 41 (37.6) 0.08 0.12 1.50 0.126
  II 51 (46.8) 0.06 0.13 2.17 0.009
  III 9 (8.3) 0.10 0.11 1.10 0.678
  Missing 1 (0.9)
ap<0.05 was considered significant according to non-parametric Wilcoxon signed-rank test. Significant results are indicated in bold.
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post-menopause status (fold-change, 2.20; p=0.003) and who 
had <40 years of fertile status (<30 years: fold-change, 3.75; 
p=0.041; 30-40 years: fold-change, 2.40; p=0.005) also 
presented increased expression of miR-203a in tumor 
tissues compared to adjacent normal tissues. Regarding 
the number of pregnancies, patients with >4 pregnancies 
showed a significantly increased expression of miR-203a 
in tumor tissues (fold-change, 4.00; p=0.001). These results 
are in accordance with the ones described above where 
Kruskal-Wallis test was applied. In accordance, although not 
significantly, women with >4 children showed an increased 
expression of miR-203a. Patients with first childbirth before 
20 years of age also showed an increased expression of 
miR-203a (fold-change, 3.40; p=0.033). Breastfeeding status 
and oral contraceptive consumption also showed statistically 
significant results (Table I).
Association between miR-203a expression and lifestyle char-
acteristics. It is known that various lifestyle habits can be a 
risk factor for cancer. In our series we included body mass 
index and smoking and alcohol habits. Overweight patients 
showed an increase in miR-203a expression in tumor tissues 
(fold-change, 2.75; p=0.006) and those who did not smoke 
(fold-change, 2.60; p=0.001) or sporadically drank alcoholic 
beverages (fold-change, 3.00; p=0.037) also showed an 
increased expression of miR-203a (Table II).
Association between miR-203a expression and clinico-
pathological characteristics. Several clinicopathological 
characteristics showed an association with miR-203a expres-
sion (Table III). Tumors with diameter ≤18.5 mm, showed 
significant difference, albeit with a slight fold-change 
of 1.5 compared with adjacent normal tissue (p=0.019), 
together with tumors positive for ER (fold-change, 1.71; 
p=0.042), PR (fold-change, 1.50; p=0.046), negative for 
HER2 (fold-change, 1.50; p=0.016) and Ki-67 index (fold-
change, 2.60; p=0.024). Tumors that did not invade the 
lymph nodes also presented higher expression of miR-203a 
(fold-change, 2.40; p=0.013). With regard to histological 
classification, ductal carcinomas in situ (fold-change, 2.20; 
p=0.028) and invasive carcinoma NOS (fold-change, 1.71; 
p=0.009) showed a significantly higher expression of miR-
203a. Stage 0 and II also showed significantly increased 
expression (fold-change, 2.20; p=0.028; fold-change, 2.17; 
p=0.009, respectively). When considering only invasive 
lobular tumors significant differences were found in staging, 
mainly when comparing stage III with stage I (Fig. 4).
Discussion
Several studies have established that specific miRNA expres-
sion patterns can be correlated with biological and clinical 
features. Studies of miRNA expression patterns in different 
populations are of utmost importance in order to unveil the 
significance of these molecules in the diagnosis and prognosis 
of breast cancer. In the present study, we showed that miR-203a 
was overexpressed in tumor tissues when compared to adjacent 
normal tissues in a Portuguese cohort. To our knowledge this 
is the first study to report miR-203a expression in a Portuguese 
breast cancer population. Our results are in accordance with 
another study by Ru et al (24). However, they did not compare 
adjacent normal tissues with tumor tissues but an independent 
disease-free population. The same pattern of overexpression 
was also observed in ovarian cancer (39), cervical cancer (40), 
kidney and bladder cancers (22), colon adenocarcinoma (41) 
and head and neck squamous cell carcinoma (42). Conversely, 
miR-203 expression levels were decreased in hepatocellular 
carcinoma (43). Altogether these data support the notion that 
miR-203a plays an important role in the development of cancer 
in a tissue-specific manner.
In the present study, we compared miR-203a expression 
levels in ductal carcinoma in situ (n=7), invasive carcinoma 
NOS (n=91) and invasive lobular carcinoma (n=10). Our 
sample population also comprised one mixed tumor (invasive 
ductal and lobular carcinoma) but this was not considered in 
the statistical analysis of the histological subtypes. Comparing 
matched samples, we observed significant differences between 
miR-203a levels in the tumor and adjacent normal tissues in 
Figure 3. Differences in the fold-change in miR-203a expression between 
categories of age at diagnosis. The values of miR-203a expression levels 
are shown in arbitrary units as determined by 2-ΔΔCt method [ΔΔCt = ΔCt 
(tumor) - ΔCt (adjacent normal)]. Bars represents mean and error bars, SEM. 
p<0.05 was considered significant according to the non-parametric Kruskal-
Wallis test.
Figure 4. Differences in the fold-change in miR-203a expression between 
tumor stages in invasive lobular carcinoma. The values of miR-203a expres-
sion levels are shown in arbitrary units as determined by 2-ΔΔCt method 
[ΔΔCt = ΔCt (tumor) - ΔCt (adjacent normal)]. Bars represents mean and 
error bars, SEM. p<0.05 was considered significant according to the 
non-parametric Kruskal-Wallis test.
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the ductal carcinoma in situ and invasive carcinoma NOS. 
However, there were no significant differences between the 
two groups. Due to the fact that two different types of breast 
tumors were presented, ductal and lobular, we analyzed 
ductal carcinoma in situ and invasive carcinoma NOS sepa-
rately. However, we did not find significant differences either. 
Nevertheless, we highlight the fact that there was a decrease 
in the miR-203a expression level in invasive carcinoma NOS 
when compared with ductal carcinoma in situ. These results 
suggest that during tumor development, miR-203a may 
be downregulated, thus suggesting that miR-203a may be 
implicated in early stages of tumor development. Indeed, this 
involvement of miR-203a in invasiveness through inhibition of 
the Polycomb group gene BMI1 has alreadybeen  reported in 
melanoma (34) and non-small cell lung cancer (26), in which 
miR-203a expression levels are inversely correlated with BMI1 
expression levels according to the cell type. Zhang et al (25) 
also reported an increased expression of miR-203a in breast 
tumors compared to matched adjacent normal tissue, even 
though their cohort was smaller. Additionally, the authors deter-
mined miR-203a expression levels in several non-tumorigenic, 
non-metastatic and metastatic breast cell lines and showed an 
increased expression of miR-203a in non-metastatic compared 
to non-tumorigenic and metastatic lines. These results led 
the authors to speculate that miR-203a is overexpressed in 
a protective mechanism to deal with cell proliferation and 
invasiveness, and thereafter, most probably through epigenetic 
mechanisms, the tumor cells repress miR-203a expression 
to enable proliferation, invasion and metastasis through 
increased expression of the pro-metastatic gene SNAI2. In 
fact, our data are in accordance with this report, since when 
we stratified the tumors according to lymph node invasion, 
the tumors that metastasized had a decreased expression of 
miR-203a (fold-change expression, 1.22; n=53; Table III) 
compared to those that did not metastasize to the lymph node 
(fold-change expression, 2.40; n=52; Table III), although the 
result was not statistically different. Additionally, we also 
found that miR-203a had decreased expression in tumors 
positive for HER2 and a high level for the proliferation index 
Ki-67 (Table III). Altogether these data are in accordance with 
the fact that miR-203a may act as a tumor suppressor, and 
in early stages of cancer development miR-203a may play a 
protective role. Yet, throughout tumor development, miR-203a 
may be repressed in order to enable tumor cells to proliferate, 
invade and metastasize.
Notably, miR-203a expression decreased from stage 0 
to stage I, then increased in stage II, and again decreased 
in stage III. This upregulation and downregulation across 
stages was unexpected, since as a putative tumor suppressor, 
miR-203a expression should decrease with increasing stages. 
Petrovic et al (44) observed a similar pattern in invasive breast 
carcinomas but with miR-21. miRNA levels are dependent 
on cell differentiation, thus displaying differently expression 
levels according to stage. Analyzing only invasive lobular 
carcinoma tumors, there were significant differences between 
stage I (n=2), II (n=6) and III (n=2). Although the number 
of samples was small, we observed a pronounced decrease 
in miR-203a expression within the stages (Fig. 4). Thus, 
miR-203a expression levels in invasive lobular carcinoma can 
be used as a marker to distinguish different stages.
Breast cancer risk increases with age. However, indi-
vidual risk depends on other factors, including reproductive 
history, lifestyle habits and family history, among others. 
Our data showed significant differences with age stratifica-
tion. Indeed, women over 60 years at diagnosis presented 
an increased expression of miR-203a when tumor tissue was 
compared with adjacent normal tissue. As estimated by The 
Surveillance, Epidemiology, and End Results (SEER) program 
of the National Cancer Institute (45), there is a risk increment 
for developing breast cancer with age. Our stratification was 
carried out using the same criteria, and we observed a higher 
expression of miR-203a in patients above 60 years of age. 
Regarding age at menarche and age at menopause, known 
players for breast cancer, the expression levels were higher 
for matched samples for age at menarche >13 years and for 
age at menopause <50 years. Although we observed signifi-
cant differences in matched samples for the classes referred, 
there were no differences for age at menarche and menopause 
classes indicating that miR-203a expression levels were not 
influenced by these factors.
Furthermore, it is known that female hormones, such as 
17-β-estradiol (E2), regulate gene expression by binding to 
estrogen receptors (46). Indeed, Yu et al (27), showed that 
E2 can regulate miRNA expression and thus control cell 
proliferation. The authors showed that miR-16, miR-143 and 
miR-203a expression was suppressed after E2 stimulation 
hence upregulating bcl-2, cyclin D1 and survivin. Thus, the 
authors proposed a mechanism whereby cells that undergo 
stimulation by E2 have increased proliferation by inhibiting 
tumor suppressor miRNAs involved in cell proliferation and 
survival. Additionally, the authors ascertained the expression 
levels of these miRNAs in triple-positive and triple-negative 
breast tumors and showed that they had increased levels of 
expression in triple-positive tumors, indicating that these 
miRNAs may function as tumor suppressors in triple-positive 
breast tumors. In contrast, our data showed that triple-positive 
samples had lower expression of miR-203a than triple-negative 
tumors (data not shown). Indeed, when we stratified our 
data according to hormone receptor status, individually, we 
obtained always an increased expression level of miR-203a in 
tumors with negative receptor status. When sample matching 
was analyzed we found significant differences between tumor 
tissues and adjacent normal tissues with positive status. To 
confirm these data, when we analyzed the samples by strati-
fying them by molecular subtype, we observed that basal-like 
tumors had higher expression of miR-203a. Although the terms 
basal-like tumor and triple-negative tumors are not used inter-
changeably (3), in this case we can consider that all basal-like 
were triple-negative tumors. Interestingly, women who had 
used oral contraceptives had lower expression of miR-203a in 
these tissues. Thus, miR-203a expression might be influenced 
by estrogen and progesterone (27).
In summary, miR-203a appears to be involved in breast 
cancer development, mainly in the early stages of develop-
ment. Early-stage tumor cells might upregulate miR-203a in 
a self-protective manner in order to manage the augmented 
cell proliferation and then, most probably, through epigenetic 
mechanisms or E2 mediated suppression, miR-203a might 
be downregulated and its targets upregulated. Accordingly, 
miR-203a could represent a potential marker for invasiveness. 
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In the present study, we also showed that miR-203a may be 
a potential marker to discriminate stages in invasive lobular 
carcinoma. Further studies with larger populations of invasive 
lobular carcinoma cases must be performed in order to vali-
date these results.
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